Weak Spots Blight Novartis Third Quarter As New Products Shine
A mixed sales bag for the Swiss major in Q3 saw a strong start for Pluvicto dampened by a reverse for Zolgensma, weak growth for Cosentyx and continued sluggishness for Leqvio. Positive data for potential blockbuster iptacopan were another bright spot, as Novartis prioritizes the delivery of high value medicines, and concentrates on the US market.
You may also be interested in...
Buy-And-Bill A Bust For Novartis's Leqvio?
The US commercial strategy for the PCSK9 inhibitor Leqvio was tied to reimbursement under Medicare Part B, but it hasn't developed the way Novartis envisioned.
Novartis Poised To Face Off With AstraZeneca In PNH After Second Iptacopan Trial
The Phase III APPOINT-PNH study, testing iptacopan in treatment-naïve PNH patients, met its primary endpoint, positioning the oral drug as a potential new competitor to Soliris and Ultomiris.
Novartis Eyes Broader Market As Pluvicto Hits Mark In Pivotal Second-Line mCRPC Trial
The major’s radioligand therapy has succeeded in an earlier line of prostate cancer therapy that presents a large market opportunity, but some observers are keen to see full data before raising their sales projections.